Logo

Illumina TruSight Oncology 500 HRD Assay

Jun 23, 2022

Illumina has launched the TruSight Oncology 500 HRD assay, a next-generation sequencing-based clinical assay for homologous recombination deficiency status. The test, codeveloped with Merck and based on validated HRD technology from Myriad Genetics, analyzes more than 500 genes, including those relevant to HRD status. HRD signatures occur when cells are unable to effectively repair double-strand breaks in DNA. Illumina expects to ship the kit in August, however, the test will not be available in the US and Japan.

Breaking News
The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.